NCT02137928

Carboplatin Periocular Injection for Retinoblastoma

Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical efficacy of periocular injections of carboplatin together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.

Detailed description

This study will be a phase Ⅲ open label interventional case series. Patients with retinoblastoma will be randomized to receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive carboplatin periocular on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 24 months .

Conditions

• Retinoblastoma

Interventions

Type	Name	Description
DRUG	carboplatin periocular injection	20mg/2ml carboplatin periocular injection together with chemotherapy
DRUG	chemotherapy	Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.

Timeline

• Start date: 2006-01-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2014-05-14
• Last updated: 2014-12-19

Locations

1 site across 1 country: China